Abstract
Background: There are few data about lipid profiles in unselected patients with angiographically confirmed coronary artery disease (CAD).
Hypothesis: The study was undertaken to investigate the demographics, clinical characteristics, angiographic findings, and baseline lipid status of 1,000 consecutive unselected patients with angiographically confirmed CAD.
Methods: Between April 2001 and July 2002, we obtained informed consent and prospectively collected clinical characteristics, fasting lipid profiles, and angiographic results from 1,000 sequential patients with CAD confirmed by angiography.
Results: In these patients with confirmed CAD, 78% had history of hyperlipidemia. Although 62% were receiving lip‐id‐lowering therapy, only 46% had a low‐density lipoprotein target of < 100 mg/dl, and only 20% had achieved all four National Cholesterol Education Program‐recommended lip‐id targets.
Conclusions: Better strategies to ensure optimal lipid levels are required. One such method using computerized workflow is being evaluated in this population.
Keywords: atherosclerosis, dyslipidemia, coronary angiography
Full Text
The Full Text of this article is available as a PDF (26.2 KB).
References
- 1. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA: Ten‐year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700–1717 [DOI] [PubMed] [Google Scholar]
- 2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, 163: for the West of Scotland Coronary Prevention Study Group : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
- 3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Landendorfer A, Stein EA, Kruyer W, Gotto AM Jr, 183: for the AFCAPS/ TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels : Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease : The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 44: 1383–1389 [PubMed] [Google Scholar]
- 5. Sacks FM, Pfeffer MA, Moyé L, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
- 6. The Long‐term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
- 7. Heart Protection Study Collaborative Group : MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360: 7–22 12114036 [Google Scholar]
- 8. Pederson TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jonsson B, Schwartz JS: Cholesterol lowering and the use of healthcare resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796–1802 [DOI] [PubMed] [Google Scholar]
- 9. Yusuf S, Anand S: Cost of prevention: The case of lipid lowering. Circulation 1996; 93: 1774–1776 [DOI] [PubMed] [Google Scholar]
- 10. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project—a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–467 [DOI] [PubMed] [Google Scholar]
- 11. Marcello JJ, Feingold K: Inadequate treatment with HMG‐CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605–610 [DOI] [PubMed] [Google Scholar]
- 12. American Heart Association 2002 Heart and Stroke Statistical Update Dallas , Texas, AHA 2001.
- 13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults : Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497 [DOI] [PubMed] [Google Scholar]
- 14. Castelli WP, Anderson K, Wilson PW, Levy D: Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol 1992; 2: 23–28 [DOI] [PubMed] [Google Scholar]
- 15. Assman G, Schulte H, von Eckardstein A, Huang Y: High‐density lipoprotein cholesterol as a predictor of coronary heart disease risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atheroscerosis 1996; 124 338: (suppl): S11–S20 [DOI] [PubMed] [Google Scholar]
- 16. Assmann G, Schulte H, Funke H, von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998; 19 352: (suppl M): M8–M14 [PubMed] [Google Scholar]
- 17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, 370: for the Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group . Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high‐density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418 [DOI] [PubMed] [Google Scholar]
- 18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle‐aged men with dylipidemia: Safety of treatment, changes in risk factors, and the incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–1245 [DOI] [PubMed] [Google Scholar]
- 19. Shepherd J, Hunnihake DB, Barter P, McKenny JM, Hutchinson HG: Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid‐lowering goals. Am J Cardiol 2003; 91: 11–17 [DOI] [PubMed] [Google Scholar]
- 20. De Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT‐705, in humans: A randomized phase II dose response study. Circulation 2002; 105: 2159–2165 [DOI] [PubMed] [Google Scholar]